TB Alliance

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
Monday, March 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 24, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
Monday, March 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

Vast Therapeutics Expands Leadership Team with Appointment of Dr. Paul Bruinenberg as Chief Medical Officer

Retrieved on: 
Thursday, March 7, 2024
Rochester University, Bronchiectasis, Roche, Cystic fibrosis, MD, NIH, Medical director, Nephrotoxicity, Astellas Pharma, MBA, TB, ARUP Laboratories, University of Utah, University, Therapy, Pathology, TB Alliance, Associate, Patient, Duke University, Diagnosis, Tuberculosis, Pseudomonas aeruginosa, NTM, Publication, IND, Pharmaceutical industry

MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer. Dr. Bruinenberg brings over 30 years of experience as a clinical development executive in respiratory medicine and orphan diseases. This appointment and the recent addition of microbiologist and clinical diagnostics expert Chris Polage, MD, as Medical Director, significantly bolster the company's clinical development expertise in pulmonary infectious diseases and medical microbiology. 

Key Points: 
  • MORRISVILLE, N.C., March 7, 2024 /PRNewswire/ -- Vast Therapeutics today announced the addition of Paul Bruinenberg, MD, MBA as Chief Medical Officer.
  • "Paul's development experience will guide Vast Therapeutics as we successfully transition to a clinical-stage organization," said Nate Stasko, Chief Executive Officer at Vast Therapeutics.
  • "It is an amazing opportunity to join a company with an accepted IND for a novel treatment modality that shows promising efficacy against chronic infections caused by Pseudomonas aeruginosa and non-tuberculosis mycobacteria," commented Paul Bruinenberg, Chief Medical Officer at Vast Therapeutics.
  • Most recently, Dr. Bruinenberg served as the Senior Medical Officer of the TB Alliance leading clinical development against mycobacterial infections.

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Medicine, Tuberculosis, Senior, Miliary tuberculosis, WHO, Patient, Infection, Pretomanid, Stop TB Partnership, Moxifloxacin, Dauntless (video game), Linezolid, Market access, TB Alliance, TB, Pharmaceutical industry, Colin Munro MacLeod

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points: 
  • Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
  • Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
  • Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
  • BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

TB Alliance Applauds Macleods' Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Medicine, Tuberculosis, Senior, Miliary tuberculosis, WHO, Patient, Infection, Pretomanid, Stop TB Partnership, Moxifloxacin, Dauntless (video game), Linezolid, Market access, TB Alliance, TB, Pharmaceutical industry, Colin Munro MacLeod

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Indian pharmaceutical company Macleods has become the second manufacturer to launch pretomanid, a new medicine and essential component of shortened, World Health Organization (WHO)-recommended treatment regimens for drug-resistant tuberculosis (DR-TB). Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries. Macleods has recently commenced supplying pretomanid to the Stop TB Partnership's Global Drug Facility for distribution of the medicine to those countries.

Key Points: 
  • Under license from TB Alliance, Macleods will be able to supply to 135 low- and middle-income countries.
  • Pretomanid was developed by the nonprofit TB Alliance, as part of the all-oral, six-month BPaL (bedaquiline + pretomanid + linezolid) regimen used with or without moxifloxacin (BPaL/M).
  • Previously, drug-resistant TB treatment lasted 9 to 18 months or longer and often required people to take up to 14,000 pills over the course of treatment.
  • BPaL is the first set treatment regimen recommended to treat drug-resistant TB.

Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen

Retrieved on: 
Monday, September 18, 2023
Interim, TB Alliance, Royal Army Service Corps, Senior, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Margaret Chan, World Health Organization, Miliary tuberculosis, Market access, National Tuberculosis Institute, Innovation, Foreign Affairs, Doctor of Philosophy, Ministry, KOICA, Public health, South Korea, Patient, ITRC, Korea International Cooperation Agency, Physician, MOU, Republican, WHO, Pharmaceutical industry, Heating, ventilation, and air conditioning, Tuberculosis, TB, Dauntless (video game), Republic

PRETORIA, South Africa, Sept. 18, 2023 /PRNewswire/ -- Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± Moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).

Key Points: 
  • Launched in 2020 , LIFT-TB is a program intended to broaden adoption and scale-up of innovative TB cures.
  • As part of LIFT-TB, Kyrgyzstan, Ukraine and Uzbekistan each completed operational research of the BPaL regimen.
  • They have also all committed to scaling up use of the treatment for drug-resistant TB.
  • "It is heartening to see countries participating in LIFT-TB emerge as leaders in scaling up access to new DR-TB treatments.

Kyrgyzstan, Ukraine, and Uzbekistan Update National Guidelines for Drug-Resistant TB Treatment to Advance National Rollout of Three-Drug, Six-Month Regimen

Retrieved on: 
Monday, September 18, 2023
Interim, TB Alliance, Royal Army Service Corps, Senior, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Margaret Chan, World Health Organization, Miliary tuberculosis, Market access, National Tuberculosis Institute, Innovation, Foreign Affairs, Doctor of Philosophy, Ministry, KOICA, Public health, South Korea, Patient, ITRC, Korea International Cooperation Agency, Physician, MOU, Republican, WHO, Pharmaceutical industry, Heating, ventilation, and air conditioning, Tuberculosis, TB, Dauntless (video game), Republic

PRETORIA, South Africa, Sept. 18, 2023 /PRNewswire/ -- Kyrgyzstan, Ukraine, and Uzbekistan — participants in the LIFT-TB project — have updated their National Tuberculosis (TB) Clinical Guidelines to endorse the all-oral, six-month BPaL/M (bedaquiline + pretomanid + linezolid ± Moxifloxacin) regimen(s) as the national standard for treating most patients with drug-resistant tuberculosis (DR-TB).

Key Points: 
  • Launched in 2020 , LIFT-TB is a program intended to broaden adoption and scale-up of innovative TB cures.
  • As part of LIFT-TB, Kyrgyzstan, Ukraine and Uzbekistan each completed operational research of the BPaL regimen.
  • They have also all committed to scaling up use of the treatment for drug-resistant TB.
  • "It is heartening to see countries participating in LIFT-TB emerge as leaders in scaling up access to new DR-TB treatments.

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Retrieved on: 
Monday, August 14, 2023
PVT, Partnership, TB Alliance, Public, TB, Linezolid, Miliary tuberculosis, Ministry of National Health Services, Regulation and Coordination, Medicine, Dauntless (video game), Government, Patient, Tuberculosis, Remington, WHO, Moxifloxacin, World Health Organization, Disease, Pharmaceutical industry

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

Key Points: 
  • Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB.
  • Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.
  • "Remington is proud and thrilled to collaborate with TB Alliance to provide solutions that could change the lives of drug-resistant TB patients in Pakistan.
  • The partnership with Remington is part of TB Alliance's global commercialization strategy for pretomanid as part of the BPaL/BPaLM regimens.

TB Alliance Announces Partnership with Remington Pharmaceuticals to Commercialize New Therapy for Drug-Resistant Forms of TB in Pakistan

Retrieved on: 
Monday, August 14, 2023
PVT, Partnership, TB Alliance, Public, TB, Linezolid, Miliary tuberculosis, Ministry of National Health Services, Regulation and Coordination, Medicine, Dauntless (video game), Government, Patient, Tuberculosis, Remington, WHO, Moxifloxacin, World Health Organization, Disease, Pharmaceutical industry

NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

Key Points: 
  • Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB.
  • Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.
  • "Remington is proud and thrilled to collaborate with TB Alliance to provide solutions that could change the lives of drug-resistant TB patients in Pakistan.
  • The partnership with Remington is part of TB Alliance's global commercialization strategy for pretomanid as part of the BPaL/BPaLM regimens.

Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders

Retrieved on: 
Monday, May 1, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, CARD, Defense Policy Board Advisory Committee, Activism, TB Alliance, Therapy, Share repurchase, ALL, Ipsen, Internet, Stock dilution, Roche, NYU, Clinical trial, GOLD, Cancer, New York University Grossman School of Medicine, Bristol Myers Squibb, History, Bangladesh Technical Education Board, Yangon City Development Committee, Harvard Medical School, Dana–Farber Cancer Institute, Committee, Clearly, Patient, Investment, Risk, Yale New Haven Health System, Stanford University School of Medicine, Growth, Lavender Hill Mob (gay activist group), R, ANDA, Letter, Massachusetts General Hospital, D, Pharmaceutical industry, Fine chemical, Management, Medical device, Audit, Security (finance), Takeda, Exelixis, Farallon

The Exelixis stock price has experienced headwinds due to ongoing abbreviated new drug application (ANDA) legal proceedings.

Key Points: 
  • The Exelixis stock price has experienced headwinds due to ongoing abbreviated new drug application (ANDA) legal proceedings.
  • Underpinning the execution of our strategy is a disciplined capital plan that strikes the right balance between strategic R&D investment and returning capital to shareholders.
  • Rather, Farallon has continually demanded that Exelixis return capital to shareholders, which the Company has already committed to and Farallon itself has acknowledged.
  • If you received this letter by email, you may also vote by pressing the “VOTE NOW” button in the accompanying email.